TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics is a biotechnology company in the business of engineering T cells to attack cancer. Its technology platform, called T cell receptor engineering, takes immune cells from patients and reprograms them to recognize and destroy tumor cells marked by specific genetic signatures. The company is years away from knowing whether its approach will work in patients, but early clinical results and the scientific logic behind the approach have attracted investor and clinical attention. TScan’s story is inseparable from the larger narrative of cell therapy—the field’s struggle to move from blood cancers, where it has had early wins, into solid tumors, where the tumors are harder to kill and the engineering challenges are steeper.

“We are focused on advancing this program for patients with AML and MDS—bringing a transformative new approach to patients with limited treatment options.”

TScan’s lead program is focused on a specific clinical problem: preventing relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after they receive a bone marrow transplant. The company calls this the ALLOHA trial. The logic is straightforward: patients with these blood cancers have received a transplant to reset their immune system, but cancer often comes back. TScan’s idea is to infuse engineered T cells that recognize tumor-associated antigens shortly after transplant, so the newly reconstituted immune system has a trained squad of cells on patrol for cancer cells before they establish themselves. The company reported data from early patients in 2024 and 2025, and is now working toward a pivotal trial design that the FDA has agreed to after recent meetings.

The company’s second program, called PLEXI-T, targets solid tumors with a different strategy. Rather than infusing a single T cell line, TScan is building something it calls the ImmunoBank—a library of T cell receptor therapies that target different cancer-associated antigens and present on different human immune types. The idea is to treat patients with multiple T cell lines at once, the logic being that tumors are heterogeneous and will vary in which antigens they express, so hitting them with multiple engineered cell lines reduces the chance of escape. TScan paused enrollment in PLEXI-T in 2025 to shift resources toward the preclinical work needed to bring these cells to life in the patient’s body, rather than infusing them from outside—what is called in vivo engineering. That pivot signals that early results shifted the company’s thinking about the most likely path to efficacy.

Manufacturing is the hard unglamorous side of cell therapy, and it is often the difference between a technology that works on paper and one that works in patients. TScan has been iterating on its manufacturing process and reports having achieved a commercial-ready process. The FDA meeting that yielded a clear pivotal trial design also validated the manufacturing approach, which reduces execution risk relative to where TScan was a year ago.

The broader context for T cell receptor therapy

TScan sits in a specific corner of cancer immunotherapy. The field is large and includes checkpoint inhibitors (drugs that take the brakes off the immune system), antibody therapies, and engineered cell therapies. Among engineered cell approaches, CAR-T therapy—chimeric antigen receptor T cells—has been the success story so far, with four approved treatments and more in late-stage trials. CAR-T works well in blood cancers and is durable in responsive patients, but has struggled with solid tumors because solid tumors are hard to target and because the hostile microenvironment around a solid tumor can suppress engineered immune cells.

T cell receptor therapy is an older approach that has been revived by advances in genetic sequencing and cell engineering. The TCR recognizes fragments of mutated proteins inside cancer cells, presented on the surface. Because TCRs can recognize a wider universe of cancer-associated proteins than CAR-T systems, proponents argue that TCR-engineered cells might be more broadly applicable, especially in solid tumors. But that advantage is also speculative: no TCR therapy has yet been approved for any cancer. TScan, alongside a handful of competitors, is trying to be the first.

The risks

TScan is a clinical-stage company with no approved products and no revenue. The financial runway is limited. The company would need to raise additional capital to fund Phase 2 trials of the ALLOHA program and to advance PLEXI-T toward human dosing. If capital markets remain closed or investors sour on cell therapy, TScan’s path forward narrows.

Second, the science is uncertain. Early data from a few patients in a Phase 1 trial is not proof the approach works. Phase 2 will test whether the efficacy seen in early patients is reproducible and durable, and whether the side effect profile is manageable. AML is a serious disease with poor outcomes, so patients and doctors are often willing to accept safety risks. Solid tumors are a different calculation: if a TCR therapy does not work better than existing options, the bar for safety becomes higher. TScan will need to demonstrate not just that the therapy is safe enough to try, but that it works.

Third, manufacturing remains a potential bottleneck. Cell therapy manufacturing is bespoke and costly. The more TScan can drive down the cost and complexity of making its products, the better the commercial odds. But manufacturing is often where timelines slip and where the gulf between a promising preclinical process and a ready-for-patients process reveals itself.

How to research TScan as an investment

TScan files 10-K and quarterly 10-Q reports with the SEC (CIK 0001783328). These filings list the company’s clinical trials in detail, breaking down enrollment, trial objectives, and timelines. Press releases and conference calls will highlight clinical progress, especially any updates on the ALLOHA and PLEXI-T trials.

The most important metric to watch is trial enrollment and patient safety data. For ALLOHA, look for updates on how many patients have been dosed and what efficacy and safety signals have emerged. For PLEXI-T, the pause in enrollment and shift toward in vivo engineering suggests the company saw something it wanted to optimize; future updates will show whether that pivot paid off.

Also watch cash burn and capital-raising activity. How much cash does the company have, and how many quarters of runway does that represent? If management is telegraphing a financing, that is a sign the company expects to run through its current cash before achieving key milestones. Finally, track the competitive landscape. If CAR-T continues to make inroads into solid tumors—if companies like Juno Therapeutics or Novartis announce positive solid-tumor data with CAR-T—the urgency of the TCR-therapy thesis weakens. Conversely, if TScan announces a significant partnership or license deal, it signals clinical and commercial confidence.